Seminars in Oncology
Volume 32, Issue 3 , Pages 299-314 , June 2005

Advances in Cytotoxic Chemotherapy for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

References 

  1. Mountain CF . Revisions in the International System for Staging Lung Cancer . Chest . 1997;111:1710–1717
  2. Non Small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer (A meta-analysis using updated data on individual patients from 52 randomised clinical trials) . Br Med J . 1995;311:899–909
  3. Goodwin PJ , Shepherd FA . Economic issues in lung cancer (A review) . J Clin Oncol . 1998;16:3900–3912
  4. Choy H , Shyr Y , Cmelak AJ , et al.   Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. . Cancer . 2000;88:1336–1346
  5. Zatloukal P , Petruzelka L , Zemanova M , et al.   Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer (A phase III randomized trial) . Lung Cancer . 2003;41:321–331
  6. Le Chevalier T , Brisgand D , Douillard JY , et al.   Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer (Results of a European multicenter trial including 612 patients) . J Clin Oncol . 1994;12:360–367
  7. Kelly K , Crowley J , Bunn P , et al.   Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer (A Southwest Oncology Group trial) . J Clin Oncol . 2001;19:3210–3218
  8. Scagliotti GV , De Marinis F , Rinaldi M , et al.   Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer . J Clin Oncol . 2002;20:4285–4291
  9. Schiller JH , Harrington D , Belani CP , et al.   Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med . 2002;346:92–98
  10. Fossella F , Pereira JR , von Pawel J , et al.  The TAX 326 study group   Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer . J Clin Oncol . 2003;21:3016–3024
  11. Kubota K , Watanabe K , Kunitoh H , et al.  The Japanese Taxotere Lung Cancer Study Group   Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer . J Clin Oncol . 2004;22:254–261
  12. Negoro S , Masuda N , Takada Y , et al.   Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer . Br J Cancer . 2003;88:335–341
  13. Rosell R , Gatzemeier U , Betticher DC , et al.   Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer (A cooperative multinational trial) . Ann Oncol . 2002;13:1539–1549
  14. Hotta K , Matsuo K , Ueoka H , et al.   Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer . J Clin Oncol . 2004;22:3852–3859
  15. Satouchi M , Takada Y , Takeda K , et al.   Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC) (A West Japan Thoracic Oncology Group (WJTOG) Study) . Proc Am Soc Clin Oncol . 2001;20:329; (abstr 1312)
  16. Miller VA , Krug LM , Ng KK , et al.   Phase II trial of docetaxel and vinorelbine in patients with advanced non-small lung cancer . J Clin Oncol . 2000;18:1346–1350
  17. Ettinger D , Monnerat C , Kelly K , et al.   Phase II trial of pemetrexed + gemcitabine in patients with advanced non-small cell lung cancer (importance of survival over response) . Proc Am Soc Clin Oncol . 2002;21:311a; (abstr 1243)
  18. Georgoulias V , Papadakis E , Alexopoulos A , et al.   Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer (A randomised multicentre trial) . Lancet . 2001;357:1478–1484
  19. Kosmidis P , Mylonakis N , Nicolaides C , et al.   Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer (A phase III randomized trial) . J Clin Oncol . 2002;20:3578–3585
  20. Smit EF , van Meerbeeck JP , Lianes P , et al.   Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer (A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975) . J Clin Oncol . 2003;21:3909–3917
  21. Gridelli C , Gallo C , Shepherd FA , et al.   Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group) . J Clin Oncol . 2003;21:3025–3034
  22. Alberola V , Camps C , Provencio M , et al.   Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer (A Spanish Lung Cancer Group phase III randomized trial) . J Clin Oncol . 2003;21:3207–3213
  23. Pfister DG , Johnson DH , Azzoli CG , et al.   American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline (Update 2003) . J Clin Oncol . 2004;22:330–353
  24. Wozniak A , Crowley JJ , Balcerzak SP , et al.   Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer (A Southwest Oncology Group study) . J Clin Oncol . 1998;16:2459–2465
  25. Gatzemeier U , von Pawel J , Gottfried M , et al.   Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer . J Clin Oncol . 2000;18:3390–3399
  26. Sandler AB , Nemunaitis J , Denham C , et al.   Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer . J Clin Oncol . 2000;18:122–130
  27. von Pawel J , von Roemeling R , Gatzemeier U , et al.   Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors . J Clin Oncol . 2000;18:1351–1359
  28. Lilenbaum R , Herndon J , List M , et al.   Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC) (A CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness) . Proc Am Soc Clin Oncol . 2002;21:1a; (abstr 2)
  29. Sederholm C . Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC) (A phase III study by the Swedish Lung Cancer Study Group (SLUSG)) . Proc Am Soc Clin Oncol . 2002;21:291a; (abstr 1162)
  30. Georgoulias V , Ardavanis A , Agelidou M , et al.   Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC) . Proc Am Soc Clin Onc . 2002;21:291a; (abstr 1163)
  31. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer . J Clin Oncol . 1997;15:2996–3018
  32. Vansteenkiste J , Vandebroek J , Nackaerts K , et al.   Clinical-benefit response in advanced non-small cell lung cancer (A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine) . Ann Oncol . 2001;12:1221–1230
  33. Perng RP , Chen YM , Ming-Liu J , et al.   Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study . J Clin Oncol . 1997;15:2097–2102
  34. Manegold C, Drings P, von Pawel J, et al: A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. Semin Oncol 24:S8-13–S8-7, (suppl 8)
  35. Itri LM , Gralla RJ . A review of etoposide in patients with non-small cell lung cancer (NSCLC) . Cancer Treat Rev . 1982;9:115–118
  36. Itri LM , Gralla RJ , Chapman RA , et al.   Phase II trial of VP-16-213 in non-small-cell lung cancer . Am J Clin Oncol . 1982;5:45–47
  37. Georgoulias V , Ardavanis A , Agelidou A , et al.   Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer (A randomized, multicenter phase III trial) . J Clin Oncol . 2004;22:2602–2609
  38. Laack E , Dickgreber N , Muller T , et al.   Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer (From the German and Swiss Lung Cancer Study Group) . J Clin Oncol . 2004;22:2348–2356
  39. Crino L , Scagliotti GV , Ricci S , et al.   Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer (A randomized phase III study of the Italian Lung Cancer Project) . J Clin Oncol . 1999;17:3522–3530
  40. Rudd R , Gower N , James L , et al.   Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosphamide, and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC) . Proc Am Soc Clin Oncol . 2002;21:292a; (abstr 1164)
  41. Danson S , Middleton MR , O’Byrne KJ , et al.   Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma . Cancer . 2003;98:542–553
  42. Comella P , Frasci G , Panza N , et al.   Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer (Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group) . J Clin Oncol . 2000;18:1451–1457
  43. Bunn PA , Lilenbaum R . Chemotherapy for elderly patients with advanced non-small-cell lung cancer . J Natl Cancer Inst . 2003;95:341–343
  44. Giaccone G , Herbst RS , Manegold C , et al.   Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer (A phase III trial—INTACT 1) . J Clin Oncol . 2004;22:777–784
  45. Herbst RS , Giaccone G , Schiller JH , et al.   Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer (A phase III trial-INTACT 2) . J Clin Oncol . 2004;22:785–794
  46. Herbst R , Prager D , Hermann R , et al.   TRIBUTE—A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) . Proc Am Soc Clin Oncol . 2004;23:617; (abstr 7011)
  47. Gatzemeier U , Pluzanska A , Szczesna A , et al.   Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) . Proc Am Soc Clin Oncol . 2004;23:617; (abstr 7010)
  48. Miller VA , Kris MG , Shah N , et al.   Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer . J Clin Oncol . 2004;22:1103–1109
  49. Tortora G , Ciardiello F . Antisense strategies targeting protein kinase C (Preclinical and clinical development) . Semin Oncol . 2003;30(suppl 10):26–31
  50. Villalona-Calero MA , Ritch P , Figueroa JA , et al.   A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer . Clin Cancer Res . 2004;10:6086–6093
  51. Smith IE , O’Brien ME , Talbot DC , et al.   Duration of chemotherapy in advanced non-small-cell lung cancer (A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin) . J Clin Oncol . 2001;19:1336–1343
  52. Socinski MA , Schell MJ , Peterman A , et al.   Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer . J Clin Oncol . 2002;20:1335–1343
  53. Belani CP , Barstis J , Perry MC , et al.   Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation . J Clin Oncol . 2003;21:2933–2939
  54. Hickish TF , Smith IE , Middleton G , et al.   Patient preference for extended palliative chemotherapy for non-small cell lung cancer . Lancet . 1995;345:857–858 (letter)
  55. Shepherd FA , Dancey J , Ramlau R , et al.   Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy . J Clin Oncol . 2000;18:2095–2103
  56. Dancey J , Shepherd F , Ramlau R , et al.   Quality of life (QOL) assessment in a randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy . Proc Am Soc Clin Oncol . 1999;18:491a; (abstr 1896)
  57. Fossella FV , DeVore R , Kerr RN , et al.   Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small lung cancer previously treated with platinum-containing chemotherapy regimens . J Clin Oncol . 2000;18:2354–2362
  58. Miller V , Fossella F , DeVore R , et al.   Docetaxel (D) benefits lung cancer symptoms and quality of life (QoL) in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum-based therapy . Proc Am Soc Clin Oncol . 1999;18:491a; (abstr 1895)
  59. Canfield V , Garfield D , Gregurich R , et al.   Phase II trial of single-agent, weekly docetaxel as second-line therapy in patients with advanced non-small cell lung cancer . Proc Amer Soc Clin Oncol . 2002;21:239b; (abstr 2775)
  60. Schütte W , Nagel S , Lautenschläger C , et al.   Randomized phase II study of weekly versus three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) . Proc Am Soc Clin Oncol . 2002;21:308a; (abstr 1228)
  61. Bunn P , Paoletti P , Niyikiza C , et al.   Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA) a novel antifolate/ antimetabolite . Proc Am Soc Clin Oncol . 2001;20:76a; (abstr 300)
  62. Bunn P . Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors) . Semin Oncol . 2002;29(suppl 9):17–22
  63. Hanna N , Shepherd FA , Fossella FV , et al.   Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy . J Clin Oncol . 2004;22:1589–1597
  64. Schiller J , Harrington D , Belani C , et al.   Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med . 2002;346:92–98
  65. Sweeney CJ , Zhu J , Sandler AB , et al.   Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 (A phase II trial in patients with metastatic nonsmall cell lung carcinoma) . Cancer . 2001;92:2639–2647
  66. Soria JC , Brisgand D , Le Chevalier T . Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? . Ann Oncol . 2001;12:1667–1670
  67. Le Chevalier T , Brisgand D , Douillard JY , et al.   Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer (Results of a European multicenter trial including 612 patients) . J Clin Oncol . 1994;12:360–367
  68. The Elderly Lung Cancer Vinorelbine Italian Study Group . Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer . J Natl Cancer Inst . 1999;91:66–72
  69. Roszkowski K , Pluzanska A , Krzakowski M , et al.   A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) . Lung Cancer . 2000;27:145–157
  70. Ranson M , Davidson N , Nicolson M , et al.   Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer . J Natl Cancer Inst . 2000;92:1074–1080
  71. Anderson H , Hopwood P , Stephens RJ , et al.   Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—A randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer . Br J Cancer . 2000;83:447–453
  72. Hainsworth JD , Erland JB , Barton JH , et al.   Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status (Results of a Minnie Pearl Cancer Research Network phase II trial) . Clin Lung Cancer . 2003;5:33–38
  73. McKay C , Hainsworth J , Burris H , et al.   Weekly docetaxel/gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC) (A Minnie-Pearl Cancer Research Network phase II trial) . Proc Am Soc Clin Oncol . 2001;20:260b; (abstr 2793)
  74. Earle CC , Venditti LN , Neumann PJ , et al.   Who gets chemotherapy for metastatic lung cancer? . Chest . 2000;117:1239–1246
  75. Rocha Lima CM , Herndon JE , Kosty M , et al.   Therapy choices among older patients with lung carcinoma (An evaluation of two trials of the Cancer and Leukemia Group B) . Cancer . 2002;94:181–187
  76. Kelly K , Giarritta S , Akerley W , et al.   Should older patients receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308 . Proc Am Soc Clin Oncol . 2001;20:329a; (abstr 1313)
  77. Ramalingam S , Belani C , Barstis J , et al.   Treatment of elderly non-small cell lung cancer (NSCLC) patients with three different schedules of weekly paclitaxel in combination with carboplatin (Sub-analysis of a randomized trial) . Proc Am Soc Clin Oncol . 2003;22:670; (abstr 2693)
  78. Langer C , Vangel M , Schiller J , et al.   Age-specific subanalysis of ECOG 1594 (Fit elderly patients (70–80 YRS) with NSCLC do as well as younger pts (<70)) . Proc Am Soc Clin Oncol . 2003;22:639; (abstr 2571)
  79. Kosty MP , Fleishman SB , Herndon JE , et al.   Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer (A randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B) . J Clin Oncol . 1994;12:1113–1120
  80. Clamon G , Herndon J , Copper R , et al.   Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer (A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group) . J Clin Oncol . 1999;17:4–11
  81. Langer CJ , Manola J , Bernardo P , et al.   Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer (Implications of Eastern Cooperative Oncology Group 5592, a randomized trial) . J Natl Cancer Inst . 2002;94:173–181
  82. Ricci S , Antonuzzo A , Galli L , et al.   Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer (A multicenter phase II study) . Lung Cancer . 2000;27:75–80
  83. McKay CE , Hainsworth JD , Burris HA , et al.   Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung cancer (A Minnie Pearl Cancer Research Network phase II trial) . Proc Am Soc Clin Oncol . 2000;19:502a; (abstr 1964)
  84. Fidias P , Supko JG , Martins R , et al.   A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer . Clin Cancer Res . 2001;7:3942–3949
  85. Frasci G , Lorusso V , Panza N , et al.   Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer . J Clin Oncol . 2000;18:2529–2536
  86. Gridelli C , Perrone F , Gallo C , et al.   Chemotherapy for elderly patients with advanced non-small-cell lung cancer (The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial) . J Natl Cancer Inst . 2003;95:362–372
  87. Comella P , Frasci G , Carnicelli P , et al.   Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients . Br J Cancer . 2004;91:489–497
  88. Silvestri G , Pritchard R , Welch HG . Preferences for chemotherapy in patients with advanced non-small cell lung cancer (Descriptive study based on scripted interviews) . BMJ . 1998;317:771–775
  89. Saitoh Y , Fujisawa T , Shiba M , et al.   Prognostic factors in surgical treatment of solitary brain metastasis after resection of non-small-cell lung cancer . Lung Cancer . 1999;24:99–106
  90. de Perrot M , Licker M , Robert JH , et al.   Long-term survival after surgical resections of bronchogenic carcinoma and adrenal metastasis . Ann Thorac Surg . 1999;68:1084–1085
  91. Ebright MI , Zakowski MF , Martin J , et al.   Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma . Ann Thorac Surg . 2002;74:1640–1646
  92. Miller VA , Kris MG , Shah NT , et al.   Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer . J Clin Oncol . 2004;22:1103–1109
  93. Miller V , Patel J , Shah N , et al.   The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC) (Preliminary results of a phase II trial) . Proc Am Soc Clin Oncol . 2003;22:619; (abstr)

PII: S0093-7754(05)00081-3

doi: 10.1053/j.seminoncol.2005.02.011

Seminars in Oncology
Volume 32, Issue 3 , Pages 299-314 , June 2005

Article Tools

* Image Usage & Resolution